Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMANDYSK: Amantadine Withdrawal in PD Dyskinesia
NCT00632762Phase 4Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Nov 2007
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of amantadine in levodopa-induced dyskinesia (LID) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Variation in the sum of items 32 and 33 of the UPDRS scale at 3 months. Started Nov 2007; status: completed.
02
Drugs
amantadine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT00632762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00632762.